GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » iNtRON Biotechnology Inc (XKRX:048530) » Definitions » Quality Rank

iNtRON Biotechnology (XKRX:048530) Quality Rank


View and export this data going back to 2011. Start your Free Trial

What is iNtRON Biotechnology Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

iNtRON Biotechnology Quality Rank Related Terms

Thank you for viewing the detailed overview of iNtRON Biotechnology's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


iNtRON Biotechnology Business Description

Traded in Other Exchanges
N/A
Address
137, Sagimakgol-ro, Jungwon-gu, Gyeonggi-do, Seongnam-si, KOR
iNtRON Biotechnology Inc is a Korea-based company principally engaged in the biotechnology industry. It develops, manufactures, and commercializes drugs for the treatment of infectious diseases. It is contributing to national health and national prevention through several (molecular) diagnostic products such as swine flu, VRE super bacteria, food poisoning, avian influenza and foot, and mouth disease. In addition, it is also engaged in the operation of a veterinary antibiotic alternative business and new biopharmaceuticals development business.